TESARO, Inc. (TSRO) Coverage Initiated at Evercore ISI
Equities research analysts at Evercore ISI assumed coverage on shares of TESARO, Inc. (NASDAQ:TSRO) in a research note issued on Wednesday, Marketbeat reports. The firm set an “in-line” rating and a $121.00 price target on the biopharmaceutical company’s stock. Evercore ISI’s target price indicates a potential upside of 7.09% from the company’s current price.
A number of other research firms have also recently weighed in on TSRO. Oppenheimer Holdings, Inc. assumed coverage on shares of TESARO in a research report on Thursday, May 25th. They issued an “outperform” rating and a $183.00 price objective for the company. Cann reissued an “outperform” rating on shares of TESARO in a research report on Wednesday, May 24th. Credit Suisse Group set a $198.00 price objective on shares of TESARO and gave the company a “buy” rating in a research report on Monday, June 5th. FBR & Co decreased their price objective on shares of TESARO from $200.00 to $195.00 and set a “mkt perform” rating for the company in a research report on Monday, June 5th. Finally, Wedbush raised shares of TESARO to an “outperform” rating and set a $168.00 price objective for the company in a research report on Monday, June 5th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $173.83.
TESARO (NASDAQ:TSRO) traded up 1.16% during mid-day trading on Wednesday, reaching $114.30. The company’s stock had a trading volume of 154,170 shares. The stock’s 50 day moving average price is $127.76 and its 200 day moving average price is $148.43. The stock’s market capitalization is $6.19 billion. TESARO has a 1-year low of $83.26 and a 1-year high of $192.94.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.52) by $0.30. The firm had revenue of $29.50 million during the quarter, compared to analysts’ expectations of $18.61 million. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The business’s quarterly revenue was down 17.6% on a year-over-year basis. During the same period in the previous year, the company earned ($1.28) earnings per share. Analysts expect that TESARO will post ($8.74) EPS for the current fiscal year.
In related news, VP Edward C. English sold 8,500 shares of the stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the sale, the vice president now owns 5,396 shares in the company, valued at $748,155.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 40.50% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Botty Investors LLC purchased a new position in TESARO during the second quarter valued at approximately $140,000. Nordea Investment Management AB purchased a new position in TESARO during the second quarter valued at approximately $167,000. Meeder Asset Management Inc. purchased a new position in TESARO during the first quarter valued at approximately $177,000. Oppenheimer Asset Management Inc. boosted its position in TESARO by 3,042.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,430 shares during the period. Finally, BB&T Securities LLC purchased a new position in TESARO during the second quarter valued at approximately $222,000.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.